Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iFOCUS study of histotripsy plus nivolumab and ipilimumab in advanced cancer
NL-OMON56837Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab and ipilimumab in cancer, sponsored by University Medical Center Utrecht. Primary endpoints: Safety, Tolerability and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON56837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56837.